Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia

Autor(es)

Quintino de Oliveira, Bruno ^[1] ; Catto, Luiz F. B. ^[1] ; Santana, Barbara A. A. ^[1] ; Tellechea, M. Florencia ^[1] ; Scheucher, Priscila S. ^[1] ; Scheinberg, Phillip ^[2] ; Calado, Rodrigo T. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Med Imaging Haematol & Clin Oncol, Ribeirao Preto Sch Med, Ribeirao Preto - Brazil

^[2] Hosp Beneficencia Portuguesa, Div Haematol, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: British Journal of Haematology; v. 193, n. 2 NOV 2020.
• Citações Web of Science: 1

Resumo

Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. We analysed marrow samples of AA patients who responded to immunosuppressive therapy (IST) alone or in combination with eltrombopag for the composition of the haematopoietic stem and progenitor cell (HSPC) compartment. The number of CD34(+) cells and multipotent progenitors was higher in patients treated with eltrombopag (P P < 0 center dot 05; respectively), but not the number of stem cells. No aberrant phenotype was observed. These results indicate that eltrombopag augments CD34(+) cells in vivo and preferentially expands multipotent progenitors, but not stem cells. (AU)

• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 18/25178-0 - Efeito do eltrombopague sobre a expansão de células tronco e progenitoras hematopoéticas no tratamento da anemia aplástica
• Beneficiário: Bruno Quintino de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica